Pelthos Therapeutics Inc. (PTHS)
PTHS trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1919246/000191924626000013/0001919246-26-000013-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PTHS on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Not reported by the screener |
| IPO year | 2024 |
| SEC CIK | 0001919246 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | NV |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $16.8M |
| Net income | -$43.3M |
| Operating income | -$32.4M |
| Net margin | -257.9% |
| Operating margin | -193.1% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $18.0M |
| Total assets | $130.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "The Company has evaluated principal conditions and events, in the aggregate, that may raise substantial doubt about its ability to continue as a going concern within one year from the date that these financial statements are issued." | 10-Q 2026-11-12 |
| Cash and burn | $17.7M cash; operating cash flow -$8.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 3,930,709 (2026-11-05); 3,061,681 a year earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2025-07-02 | Source 2025-07-02 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-02-02 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CBIZ CPAs P.C., Hartford, Connecticut, United States; changed auditors 2 times in 24 months | 8-K 4.01 2026-05-21 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $1000K, sold $441K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $15.4M | -$7.9M | -$5.2M | $17.7M | $38.4M | $51.3M | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $15.6M | -$23.4M | -$7.7M | $24.2M | $43.3M | $43.3M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $10.9M | -$25.1M | -$13.1M | $32.0M | $39.1M | $27.7M | 10-Q/A 2026-08-13 |
| Q4 2025 2025-12-31 | $9.4M | -$21.7M | -$6.3M | $18.0M | $31.4M | $16.8M | 10-K 2026-03-19 |
| Q3 2025 2025-09-30 | $7.4M | -$16.2M | -$15.3M | $14.2M | No debt tags | Needs four quarters | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | $0 | -$3.4M | -$447K | $59K | $132K | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $0 | -$2.0M | -$632K | $131K | $132K | Needs four quarters | 10-Q/A 2026-08-13 |
| Q4 2024 2024-12-31 | Not filed | -$1.9M | -$670K | $513K | $132K | $0 | 10-K 2026-03-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-02-13 |
| Latest annual report | 10-K | 2026-03-19 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-08-18 |
Source: SEC EDGAR submissions feed, 261 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -20.5% |
| 1 month | -63.3% |
| 3 months | -74.3% |
| Year to date | -76.0% |
| 1 year | -78.5% |
| From 52-week high | -77.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SAEN | Genenta Science S.p.A. | $0.6000 | -7.66% | $28.9M |
| CVM | Cel-Sci Corporation | $1.66 | +29.69% | $29.2M |
| INMB | INmune Bio Inc. | $0.9464 | -9.87% | $29.3M |
| LONA | LeonaBio Inc. | $3.23 | -6.92% | $30.4M |
| MGX | Metagenomi Therapeutics Inc. | $0.6800 | -1.69% | $25.7M |
| EVAX | Evaxion A/S American Depositary Share | $2.77 | +0.54% | $25.5M |
| KLRS | Kalaris Therapeutics Inc. | $1.46 | -7.30% | $34.8M |
| ELUT | Elutia Inc. | $0.8229 | +0.35% | $36.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier